Notably, a significant interaction test (HR = 0.15; 95% CI = 0.02 to 0.97, P = .047) further supports the MammaPrint Index as a predictive marker of chemotherapy benefit in H1 and H2 HR+HER2- cancers. This evidence concerns the gene ERBB2 and cancer.